Aliases & Classifications for Substance Abuse

MalaCards integrated aliases for Substance Abuse:

Name: Substance Abuse 12 28 3 14
Substance-Related Disorders 41 69
Substance Abuse Problem 69

Classifications:



External Ids:

Disease Ontology 12 DOID:302
MeSH 41 D019966
NCIt 46 C16522
SNOMED-CT 64 26416006

Summaries for Substance Abuse

Disease Ontology : 12 A substance-related disorder that involves a maladaptive pattern of substance use leading to significant impairment in functioning.

MalaCards based summary : Substance Abuse, also known as substance-related disorders, is related to eating disorder and cocaine abuse, and has symptoms including symptoms An important gene associated with Substance Abuse is DRD2 (Dopamine Receptor D2), and among its related pathways/superpathways are Peptide ligand-binding receptors and Beta-Adrenergic Signaling. The drugs Amphetamine and Aripiprazole have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and placenta, and related phenotypes are behavior/neurological and homeostasis/metabolism

CDC : 3 Data are for the U.S.

Wikipedia : 72 Substance abuse, also known as drug abuse, is a patterned use of a drug in which the user consumes the... more...

Related Diseases for Substance Abuse

Diseases in the Substance Abuse family:

T-Substance Anomaly

Diseases related to Substance Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 141)
# Related Disease Score Top Affiliating Genes
1 eating disorder 32.1 BDNF COMT DRD2 NPY SLC6A3 SLC6A4
2 cocaine abuse 32.0 DBH DRD2 PRL SLC6A3 SLC6A4
3 alcohol abuse 31.4 BDNF DRD2 DRD3 DRD4 GABRA2 PRL
4 antisocial personality disorder 30.7 COMT DRD2 MAOA SLC6A3 SLC6A4
5 generalized anxiety disorder 30.2 BDNF DRD2 MAOA SLC6A4
6 alcohol use disorder 30.2 DRD2 SLC6A4
7 traumatic brain injury 30.1 BDNF COMT DRD2
8 alexithymia 30.1 COMT DRD2 SLC6A4
9 brain injury 30.1 BDNF COMT DRD2
10 bipolar i disorder 30.1 BDNF COMT SLC6A4
11 pathological gambling 30.0 DRD2 DRD3 DRD4 MAOA SLC6A3 SLC6A4
12 borderline personality disorder 29.9 BDNF COMT HTR1B MAOA SLC6A4
13 personality disorder 29.9 BDNF COMT DRD2 DRD3 DRD4 HTR1B
14 tobacco addiction 29.9 COMT DRD2 MAOA SLC6A3
15 anxiety 29.9 BDNF COMT CYP2D6 MAOA NPY SLC6A3
16 post-traumatic stress disorder 29.8 BDNF COMT DRD2 MAOA SLC6A4
17 gilles de la tourette syndrome 29.7 BDNF COMT DBH DRD2 DRD4 DRD5
18 conduct disorder 29.7 COMT DBH DRD2 DRD4 DRD5 MAOA
19 bulimia nervosa 2 29.6 BDNF COMT NPY PRL SLC6A4
20 mood disorder 29.6 BDNF COMT DRD2 DRD4 HTR1B MAOA
21 schizoaffective disorder 29.6 BDNF COMT DRD2 DRD3 PRL SLC6A4
22 disease of mental health 29.1 BDNF COMT CYP2D6 DRD2 DRD3 DRD4
23 autism 29.0 BDNF COMT DRD2 DRD3 DRD4 MAOA
24 bipolar disorder 29.0 BDNF COMT DBH DRD2 DRD3 DRD4
25 substance dependence 28.8 BDNF CYP2D6 DRD2 DRD3 DRD4 DRD5
26 attention deficit-hyperactivity disorder 28.0 BDNF COMT CYP2D6 DBH DRD2 DRD3
27 alcohol dependence 27.8 BDNF COMT DBH DRD2 DRD3 DRD4
28 schizophrenia 27.4 BDNF COMT CYP2D6 DBH DRD2 DRD3
29 opioid abuse 11.3
30 cannabis abuse 11.3
31 panic disorder 1 10.9
32 antidepressant type abuse 10.9
33 hallucinogen abuse 10.9
34 phencyclidine abuse 10.9
35 amphetamine abuse 10.9
36 barbiturate abuse 10.9
37 delusional disorder 10.5 DRD2 DRD3 DRD4
38 impulse control disorder 10.5 DRD2 DRD3 DRD4
39 polysubstance abuse 10.5 COMT DRD2 DRD3
40 alcohol-induced mental disorder 10.4 DRD2 SLC6A3 SLC6A4
41 obsessive-compulsive personality disorder 10.4 DRD3 SLC6A4
42 alcoholic psychosis 10.4 DRD2 SLC6A3 SLC6A4
43 opiate dependence 10.4 DRD2 DRD3 SLC6A4
44 schizophreniform disorder 10.4 COMT DRD2 PRL
45 phobic disorder 10.4 COMT MAOA SLC6A4
46 phobia, specific 10.4 COMT MAOA
47 separation anxiety disorder 10.4 DRD4 PRL SLC6A3
48 heroin dependence 10.4 BDNF DRD2 DRD4 SLC6A3
49 atypical depressive disorder 10.4 MAOA SLC6A4
50 drug dependence 10.3 BDNF DRD2 DRD3 SLC6A4

Graphical network of the top 20 diseases related to Substance Abuse:



Diseases related to Substance Abuse

Symptoms & Phenotypes for Substance Abuse

UMLS symptoms related to Substance Abuse:


symptoms

MGI Mouse Phenotypes related to Substance Abuse:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.25 TDO2 GABRA2 BDNF HTR1B COMT MAOA
2 homeostasis/metabolism MP:0005376 10.03 SLC6A4 TDO2 TF GABRA2 BDNF COMT
3 endocrine/exocrine gland MP:0005379 9.91 SLC6A4 DRD5 BDNF HTR1B COMT DBH
4 integument MP:0010771 9.56 SLC6A4 TDO2 GABRA2 BDNF DBH DRD2
5 nervous system MP:0003631 9.53 SLC6A4 TDO2 GABRA2 BDNF COMT MAOA

Drugs & Therapeutics for Substance Abuse

Drugs for Substance Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 297)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amphetamine Approved, Illicit, Investigational Phase 4,Phase 2,Phase 1 300-62-9 3007 5826
2
Aripiprazole Approved, Investigational Phase 4,Phase 2,Phase 1 129722-12-9 60795
3
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 52485-79-7 644073 40400
4
Heroin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1 561-27-3 5462328
5
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 93-14-1 3516
6
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 76-99-3 4095
7
Varenicline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 249296-44-4 5310966
8
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
9
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1 54-11-5 89594 942
10
Cocaine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 50-36-2 446220 5760
11
Naloxone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 465-65-6 5284596
12
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1 64-17-5 702
13
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 16590-41-3 5360515
14
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2 20748-11-2, 113-45-1 4158
15
Bupropion Approved Phase 4,Phase 3,Phase 2,Phase 1 34911-55-2, 34841-39-9 444
16
Disulfiram Approved Phase 4,Phase 1 97-77-8 3117
17
Methamphetamine Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1 537-46-2 10836
18
Valproic Acid Approved, Investigational Phase 4,Phase 3 99-66-1 3121
19
Risperidone Approved, Investigational Phase 4,Phase 2 106266-06-2 5073
20
Ribavirin Approved Phase 4,Phase 3 36791-04-5 37542
21
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
22
Lorazepam Approved Phase 4 846-49-1 3958
23
Clozapine Approved Phase 4 5786-21-0 2818
24
Dextroamphetamine Approved, Illicit Phase 4,Phase 2,Phase 1 51-64-9 5826
25
Menthol Approved Phase 4,Phase 1 2216-51-5 16666
26
Citalopram Approved Phase 4,Phase 2,Phase 3,Phase 1 59729-33-8 2771
27
Sofosbuvir Approved Phase 4,Phase 3 1190307-88-0 45375808
28
Ziprasidone Approved Phase 4 146939-27-7 60854
29
Allopurinol Approved Phase 4 315-30-0 2094
30
Choline Approved, Nutraceutical Phase 4 62-49-7 305
31
Creatine Approved, Investigational, Nutraceutical Phase 4 57-00-1 586
32
Betadex Experimental Phase 4 7585-39-9 320761
33 Antipsychotic Agents Phase 4,Phase 2,Phase 1,Early Phase 1
34 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
35 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
36 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
38 Analgesics, Opioid Phase 4,Phase 3,Phase 2,Phase 1
39 Narcotic Antagonists Phase 4,Phase 3,Phase 2,Phase 1
40 Narcotics Phase 4,Phase 3,Phase 2,Phase 1
41 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Antitussive Agents Phase 4,Phase 3,Phase 2
43 Chlorpheniramine, phenylpropanolamine drug combination Phase 4,Phase 3,Phase 2
44 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1
45 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
46 Nicotinic Agonists Phase 4,Phase 3,Phase 2,Phase 1
47 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Adrenergic Agents Phase 4,Phase 2,Phase 3,Phase 1
49 Atomoxetine Hydrochloride Phase 4,Phase 2,Phase 1
50 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 908)

# Name Status NCT ID Phase Drugs
1 Cognitive Correlates of Substance Abuse - 11 Unknown status NCT00000346 Phase 4
2 Cognitive Correlates of Substance Abuse, Part 2 - 16 Unknown status NCT00000351 Phase 4
3 Improving Outcomes in Psychosis Associated With Substance Use Using Aripiprazole Unknown status NCT01155544 Phase 4
4 Integrating Buprenorphine Into HIV Treatment Unknown status NCT00241930 Phase 4
5 Smoking Cessation Treatment for Methadone Maintenance Patients Unknown status NCT01027754 Phase 4 Varenicline;Placebo
6 Associated Genes With Atomoxetine Response in Attention Deficit Hyperactivity Disorder (ADHD) Unknown status NCT01339286 Phase 4 atomoxetine
7 Buprenorphine and Integrated HIV Care Evaluation Unknown status NCT00124358 Phase 4 Buprenorphine
8 Pregnenolone Trial for Depression in Bipolar Disorders or Recurrent Major Depressive Disorder With Substance Abuse Completed NCT00223197 Phase 4 Pregnenolone
9 Depakote ER Therapy for Mania Comorbid With Substance Abuse Completed NCT00208195 Phase 4 Divalproex ER
10 Abilify Therapy for Reducing Comorbid Substance Abuse Completed NCT00208169 Phase 4 Aripiprazole
11 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
12 Pilot Study of Vyvanse™ In ADHD Adolescents at Risk for Substance Abuse Completed NCT00573534 Phase 4 Vyvanse
13 Facilitating the Adoption of Evidence-Based Depression Management in Substance Use Treatment Programs Completed NCT00137306 Phase 4
14 Divalproex ER vs. Risperidone for Bipolar Disorder With Comorbid Substance Use Disorder Completed NCT00203528 Phase 4 divalproex sodium ER;risperidone
15 Smoking Cessation in Alcoholism Treatment Completed NCT00000454 Phase 4 nicotine replacement patch
16 Citicoline for Bipolar 1 Disorder and Cocaine Dependence Completed NCT00619723 Phase 4 Citicoline;Placebo
17 The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients Completed NCT00295412 Phase 4 quetiapine (drug)
18 Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France ("RIME") Completed NCT00955162 Phase 4 Buprenorphine (Subutex);Buprenorphine/naloxone (Suboxone)
19 The Whole Day First Grade Program Completed NCT00257088 Phase 4
20 Study of Aripiprazole in Subjects With Alcoholism Completed NCT00082199 Phase 4 Aripiprazole;Placebo
21 Improving Hepatitis C Treatment in Injection Drug Users Completed NCT00148031 Phase 4 Pegylated Interferon and Ribavirin
22 Use of Naltrexone in a Clinical Setting Completed NCT00000445 Phase 4 naltrexone (Revia)
23 Control of Cognition Completed NCT01993108 Phase 4 Methylphenidate;Naltrexone;Placebo
24 Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder Completed NCT00156715 Phase 4 Quetiapine
25 Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence Completed NCT00330239 Phase 4 Paroxetine CR
26 Relapse Prevention With Varenicline Completed NCT00944554 Phase 4 Varenicline;Placebo
27 Randomized Trial of Ultrashort Psychotherapy vs Sustained-Release Bupropion for Smoking Cessation Completed NCT00484692 Phase 4 sustained-release bupropion (Zyban(R))
28 Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia Completed NCT00208143 Phase 4 Quetiapine;Risperidone
29 Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder Completed NCT00130923 Phase 4 Risperidone Long Acting;oral risperidone
30 Naltrexone Treatment for Alcoholic Women Completed NCT00000448 Phase 4 naltrexone;Placebo
31 Disulfiram Combined With Lorazepam for Alcohol Dependence and Anxiety Disorder Completed NCT00721526 Phase 4 disulfiram plus lorazepam
32 Naltrexone for Heavy Drinking in Young Adults Completed NCT00568958 Phase 4 naltrexone;placebo naltrexone
33 Treatment of Patients With Alcoholism and Attention Deficit Disorder Completed NCT00261872 Phase 4 Methylphenidate
34 The Maternal Lifestyle Study (MLS) Completed NCT00059540 Phase 4
35 Creatine as a Treatment Option for Depression in Methamphetamine Using Females Completed NCT01514630 Phase 4 Creatine monohydrate
36 Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia Completed NCT02396979 Phase 4 Methadone
37 Genetic and Brain Mechanisms of Naltrexone's Treatment Efficacy for Alcoholism Completed NCT00920829 Phase 4 Drug;Placebo
38 Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual Completed NCT00498550 Phase 4 Clozapine;Treatment as usual
39 Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist Completed NCT01673594 Phase 4 SODAS MPH;Naltrexone
40 Buprenorphine and Integrated HIV Care Completed NCT00317460 Phase 4
41 Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral Treatment Completed NCT00844272 Phase 4
42 Buprenorphine to Improve HIV Care Engagement and Outcomes (BRAVO) Recruiting NCT01936857 Phase 4 Buprenorphine/naloxone;Methadone Maintenance Therapy
43 Cognitive Behavioral Therapy for Adolescents With Attention-Deficit / Hyperactivity Disorder Recruiting NCT02566824 Phase 4 Methylphenidate or amphetamine product
44 Three Strategies for Implementing Motivational Interviewing on Medical Inpatient Units Active, not recruiting NCT01825057 Phase 4
45 Hepatitis C Treatment in PWIDs: MAT or Syringe Exchange Assisted-therapy vs Standard of Care Enrolling by invitation NCT03093415 Phase 4 elbasvir-grazoprevir (50 mg/100 mg)
46 Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection Not yet recruiting NCT03057847 Phase 4 Sofosbuvir/Velpatasvir
47 The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation Not yet recruiting NCT02935998 Phase 4 Ziprasidone
48 Telemonitoring of Uncontrolled Hypertension Not yet recruiting NCT02730052 Phase 4
49 Effect of Buprenorphine/Naloxone Continuation on Pain Control and Opioid Use Not yet recruiting NCT03266445 Phase 4 buprenorphine/naloxone
50 Houston Emergency Opioid Engagement System Not yet recruiting NCT03396276 Phase 4 Suboxone

Search NIH Clinical Center for Substance Abuse

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: substance-related disorders

Genetic Tests for Substance Abuse

Genetic tests related to Substance Abuse:

# Genetic test Affiliating Genes
1 Substance Abuse 28

Anatomical Context for Substance Abuse

MalaCards organs/tissues related to Substance Abuse:

38
Testes, Brain, Placenta, Liver, Kidney, Pituitary, Lung

Publications for Substance Abuse

Articles related to Substance Abuse:

(show top 50) (show all 733)
# Title Authors Year
1
Adding Resistance Training to the Standard of Care for Inpatient Substance Abuse Treatment in Men With Human Immunodeficiency Virus Improves Skeletal Muscle Health Without Altering Cytokine Concentrations. ( 29257793 )
2018
2
Why Don't Hospitals Prioritize Substance Abuse in Their Community Benefit Programming? ( 29346190 )
2018
3
A Shared Decision-Making Tool to Prevent Substance Abuse: Protocol for a Randomized Controlled Trial. ( 29326094 )
2018
4
The case for considering rather than ignoring race/ethnicity in substance abuse research. ( 29388881 )
2018
5
Perceptions of child protective services among pregnant or recently pregnant, opioid-using women in substance abuse treatment. ( 29433069 )
2018
6
Successful Use of Ketamine for Burst Suppression in Super Refractory Status Epilepticus Following Substance Abuse. ( 29422735 )
2018
7
Stigma as a Barrier to Substance Abuse Treatment Among Those With Unmet Need: An Analysis of Parenthood and Marital Status. ( 29307947 )
2018
8
Substance Abuse Surveillance among Construction Workers: A Proof of Concept Alternative Approach. ( 29303868 )
2018
9
Childhood trauma in schizophrenia spectrum disorders as compared to substance abuse disorders. ( 29360053 )
2018
10
Psychoactive substance abuse and dependence and its association with anxiety disorders: a population-based study of young adults in Brazil. ( 29451585 )
2018
11
Interventions for Women With Substance Abuse Issues: A Scoping Review. ( 29426381 )
2018
12
Intravenous Valproic Acid Add-On Therapy in Acute Agitation Adolescents With Suspected Substance Abuse: A Report of Six Cases. ( 29303801 )
2018
13
Gender and Cultural Adaptations for Diversity: A Systematic Review of Alcohol and Substance Abuse Interventions for Latino Males. ( 29364763 )
2018
14
Opioids and Substance Abuse: Education or Just Regulation? ( 28755098 )
2017
15
Is Kratom the New 'Legal High' on the Block?: The Case of an Emerging Opioid Receptor Agonist with Substance Abuse Potential. ( 28072812 )
2017
16
Childhood sexual abuse and substance abuse: A gender paradox? ( 27912908 )
2017
17
Differences in Psychoactive Substance Abuse Between Youths Residing in and Outside Conflict Zones as a Function of Level of Religiosity and Political Commitment. ( 28714800 )
2017
18
Socioeconomic differences in adolescent substance abuse treatment participation and long-term outcomes. ( 28088743 )
2017
19
Interagency collaboration: Strengthening substance abuse resources in child welfare. ( 28064109 )
2017
20
Brain Volume Correlates with Duration of Abstinence from Substance Abuse in a Region-Specific and Substance-Specific Manner. ( 29308437 )
2017
21
Modeling spatio-temporal variations of substance abuse mortality in Iran using a log-Gaussian Cox point process. ( 28760264 )
2017
22
Challenges in Laboratory Detection of Unusual Substance Abuse: Issues with Magic Mushroom, Peyote Cactus, Khat, and Solvent Abuse. ( 28057187 )
2017
23
The impaired anesthesiologist: what you should know about substance abuse. ( 27928715 )
2017
24
Current status and future prospects for the development of substance abuse vaccines. ( 28918668 )
2017
25
Predictors of Return Visits Among Insured Emergency Department Mental Health and Substance Abuse Patients, 2005-2013. ( 28874941 )
2017
26
Failure to get into substance abuse treatment. ( 28017185 )
2017
27
Childhood Maltreatment and Unprotected Sex among Female Juvenile Offenders: Evidence of Mediation by Substance Abuse and Psychological Distress. ( 28087129 )
2017
28
Prevalence of Substance Abuse among Students of Tehran University of Medical Sciences, Iran. ( 29299213 )
2017
29
Rescuing Israeli travellers: effects of substance abuse, mental health, geographic region of rescue, gender and age of rescuees. ( 28931135 )
2017
30
Substance abuse in the anesthesia block room by a patient. ( 28915425 )
2017
31
The relationship between ocular trauma and substance abuse in emergency department patients. ( 28705744 )
2017
32
Mental Health, Substance Abuse, and Suicide Among Homeless Adults. ( 28678621 )
2017
33
Follow-up protocol was useful for children whose parents attended emergency departments after partner violence, substance abuse or a suicide attempt. ( 28929523 )
2017
34
Did you get any help? A post-hoc secondary analysis of a randomized controlled trial of psychoeducation for patients with antisocial personality disorder in outpatient substance abuse treatment programs. ( 28068951 )
2017
35
Assessing the Mental Health, Substance Abuse, Cognitive Functioning, and Social/Emotional Well-Being Needs of Aboriginal Prisoners in Australia. ( 28823188 )
2017
36
"Keeping It Real": The Relational Effects of Trauma Among African American Women and Their Substance Abuse Treatment Counselors. ( 29294757 )
2017
37
Gender differences in substance abuse, PTSD and intentional self-harm among veterans health administration patients. ( 28013099 )
2017
38
Are There Tools to Screen Children and Adolescents in the Emergency Department With Mental Health and Substance Abuse Issues? ( 28935284 )
2017
39
Mixed methods inquiry into traditional healers' treatment of mental, neurological and substance abuse disorders in rural South Africa. ( 29261705 )
2017
40
Tinnitus, Anxiety, Depression and Substance Abuse in Rock Musicians a Norwegian Survey. ( 28723602 )
2017
41
Gender Differences in Complex Posttraumatic Stress Symptoms, and Their Relationship to Mental Health and Substance Abuse Outcomes in Incarcerated Adults. ( 29294660 )
2017
42
Decreased NOX2 expression in the brain of patients with bipolar disorder: association with valproic acid prescription and substance abuse. ( 28809856 )
2017
43
Mothers' experiences of coping with adolescent substance abuse: a phenomenological inquiry. ( 28760077 )
2017
44
Family and Peer-Group Substance Abuse as a Risk-Factor for Opioid Misuse Behaviors for a Young Adult with Cancer-Related Pain-A Case Study. ( 28910174 )
2017
45
Substance dependence among those without symptoms of substance abuse in the World Mental Health Survey. ( 28211594 )
2017
46
Offenders With Substance Abuse Who Receive Mandatory Psychiatric Treatment. ( 28939729 )
2017
47
Recovery From Substance Abuse Among Zimbabwean Men: An Occupational Transition. ( 28685660 )
2017
48
Social Support Influences on Substance Abuse Outcomes Among Sober Living House Residents with Low and Moderate Psychiatric Severity. ( 28757663 )
2017
49
Screening, Brief Intervention and Referral to Treatment: implications of SAMHSA's SBIRT initiative for substance abuse policy and practice. ( 28074569 )
2017
50
A Post-Hurricane Katrina Examination of Substance Abuse Treatment Discharges with Co-Occurring Psychiatric and Substance Use Disorders. ( 28045601 )
2017

Variations for Substance Abuse

Expression for Substance Abuse

Search GEO for disease gene expression data for Substance Abuse.

Pathways for Substance Abuse

Pathways related to Substance Abuse according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.45 DRD2 DRD3 DRD4 DRD5 GABRA2 HTR1B
2
Show member pathways
12.65 BDNF DRD2 DRD3 DRD4 DRD5
3
Show member pathways
12.47 COMT DRD2 DRD3 DRD4 DRD5 MAOA
4 12.18 DRD2 DRD3 DRD4 DRD5
6
Show member pathways
12.07 BDNF DRD2 DRD5 HTR1B NPY
7 11.93 BDNF MAOA PLP1 SLC6A4 TF
8
Show member pathways
11.86 BDNF DRD2 MAOA SLC6A3
9 11.83 CYP2D6 HTR1B MAOA SLC6A4
10
Show member pathways
11.78 DRD2 DRD3 DRD4
11 11.7 DBH MAOA TDO2
12
Show member pathways
11.62 COMT CYP2D6 SLC6A4
13
Show member pathways
11.61 DRD2 DRD3 DRD4 DRD5 HTR1B
14
Show member pathways
11.59 COMT DBH MAOA
15 11.08 HTR1B MAOA SLC6A4
16
Show member pathways
10.95 COMT DBH MAOA
17 10.92 DRD2 DRD3 DRD5
18
Show member pathways
10.77 COMT MAOA
19 10.72 COMT MAOA
20
Show member pathways
10.67 COMT MAOA SLC6A3 SLC6A4
21
Show member pathways
10.65 DBH MAOA SLC6A3 SLC6A4 TDO2

GO Terms for Substance Abuse

Cellular components related to Substance Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 9.77 COMT CYP2D6 DBH DRD2 DRD3 DRD4
2 integral component of plasma membrane GO:0005887 9.7 DRD2 DRD3 DRD4 DRD5 HTR1B SLC6A3
3 axon GO:0030424 9.56 COMT DRD2 GABRA2 SLC6A3
4 endocytic vesicle GO:0030139 8.8 DRD2 DRD3 TF

Biological processes related to Substance Abuse according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.97 DBH DRD5 HTR1B NPY PLP1
2 response to drug GO:0042493 9.93 COMT DRD2 DRD3 HTR1B SLC6A3 SLC6A4
3 response to ethanol GO:0045471 9.91 DRD2 DRD3 HTR1B SLC6A3
4 cellular calcium ion homeostasis GO:0006874 9.88 DRD3 DRD4 DRD5
5 locomotory behavior GO:0007626 9.86 DBH DRD2 DRD3 SLC6A3
6 learning GO:0007612 9.84 COMT DRD3 DRD5
7 social behavior GO:0035176 9.83 DRD3 DRD4 SLC6A4
8 visual learning GO:0008542 9.83 DBH DRD2 DRD3
9 neurotransmitter transport GO:0006836 9.82 GABRA2 SLC6A3 SLC6A4
10 feeding behavior GO:0007631 9.81 DRD2 HTR1B NPY
11 negative regulation of adenylate cyclase activity GO:0007194 9.81 DRD2 DRD3 DRD4
12 negative regulation of blood pressure GO:0045776 9.77 DRD2 DRD3 DRD5
13 associative learning GO:0008306 9.77 DBH DRD2 DRD5
14 arachidonic acid secretion GO:0050482 9.74 DRD2 DRD3 DRD4
15 regulation of dopamine secretion GO:0014059 9.72 DRD2 DRD3 HTR1B
16 response to iron ion GO:0010039 9.71 DRD2 SLC6A3
17 response to pain GO:0048265 9.71 COMT DBH
18 vasoconstriction GO:0042310 9.71 HTR1B SLC6A4
19 negative regulation of cAMP biosynthetic process GO:0030818 9.71 DRD4 HTR1B
20 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.71 DRD2 HTR1B
21 behavioral response to cocaine GO:0048148 9.71 DRD2 DRD3 DRD4
22 neurotransmitter biosynthetic process GO:0042136 9.7 SLC6A3 SLC6A4
23 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.7 DRD2 DRD5
24 negative regulation of voltage-gated calcium channel activity GO:1901386 9.7 DRD2 DRD4
25 synaptic transmission, dopaminergic GO:0001963 9.7 DRD2 DRD3 DRD5
26 ammonium transmembrane transport GO:0072488 9.69 SLC6A3 SLC6A4
27 positive regulation of renal sodium excretion GO:0035815 9.69 DRD2 DRD3
28 behavior GO:0007610 9.69 HTR1B NPY
29 negative regulation of protein secretion GO:0050709 9.69 DRD2 DRD3 DRD4
30 neurotransmitter catabolic process GO:0042135 9.68 COMT MAOA
31 catecholamine metabolic process GO:0006584 9.68 COMT MAOA
32 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.68 DRD3 DRD5
33 regulation of dopamine metabolic process GO:0042053 9.68 DRD4 SLC6A3
34 adenohypophysis development GO:0021984 9.67 DRD2 SLC6A3
35 monoamine transport GO:0015844 9.67 SLC6A3 SLC6A4
36 behavioral response to ethanol GO:0048149 9.67 DBH DRD2 DRD4
37 dopamine receptor signaling pathway GO:0007212 9.67 DRD2 DRD3 DRD4 DRD5
38 regulation of cAMP metabolic process GO:0030814 9.66 DRD2 DRD3
39 dopamine uptake involved in synaptic transmission GO:0051583 9.66 SLC6A3 SLC6A4
40 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.65 DRD2 DRD3
41 prepulse inhibition GO:0060134 9.65 DRD2 DRD3 SLC6A3
42 fear response GO:0042596 9.63 DBH DRD4
43 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.62 DRD2 DRD4
44 negative regulation of dopamine receptor signaling pathway GO:0060160 9.62 DRD2 DRD3
45 acid secretion GO:0046717 9.61 DRD2 DRD3
46 G-protein coupled receptor internalization GO:0002031 9.61 DRD2 DRD3 HTR1B
47 regulation of locomotion involved in locomotory behavior GO:0090325 9.58 DRD2 DRD3
48 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.58 DRD2 DRD3 DRD4
49 dopamine metabolic process GO:0042417 9.56 COMT DRD2 DRD3 DRD4
50 response to cocaine GO:0042220 9.55 DRD2 DRD3 DRD5 HTR1B SLC6A3

Molecular functions related to Substance Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor activity GO:0004930 9.93 DRD2 DRD3 DRD4 DRD5 HTR1B NPY
2 signal transducer activity GO:0004871 9.8 DRD2 DRD3 DRD4 DRD5 HTR1B
3 drug binding GO:0008144 9.63 CYP2D6 DRD2 DRD3 DRD4 HTR1B SLC6A3
4 neurotransmitter:sodium symporter activity GO:0005328 9.48 SLC6A3 SLC6A4
5 structural constituent of myelin sheath GO:0019911 9.43 MOBP PLP1
6 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.43 DRD2 DRD3 DRD4
7 monoamine transmembrane transporter activity GO:0008504 9.37 SLC6A3 SLC6A4
8 dopamine:sodium symporter activity GO:0005330 9.32 SLC6A3 SLC6A4
9 dopamine neurotransmitter receptor activity GO:0004952 9.26 DRD2 DRD3 DRD4 DRD5
10 dopamine binding GO:0035240 9.02 DRD2 DRD3 DRD4 DRD5 SLC6A3

Sources for Substance Abuse

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....